Literature DB >> 6886975

Estimation of absolute bioavailability assuming steady state apparent volume of distribution remains constant.

P S Collier, S Riegelman.   

Abstract

The limitations of using estimates of extent of bioavailability (F) based on the assumption that either clearance (CL) or Varea remain, constant are discussed in relation to the situation where CL changes between doses. When estimates of F assume CL to remain constant, the extent of the error is the same for all drugs where the percentage change in CL is the same. Assuming Varea to remain constant, the error in F will vary between drugs for similar percentage changes in CL and is related to the extent to which the kinetics of the disposition process deviate from a one compartment body model. A noncompartmental method is described where, provided the reference dose is given intravenously, F can be estimated based on the assumption that Vss remains constant between doses. This method is more accurate than those based on the assumption that either CL or Varea remain, constant when CL changes between doses, but is subject to error when the terminal log-linear slope of Cp vs. time better reflects the process of absorption rather than elimination.

Mesh:

Substances:

Year:  1983        PMID: 6886975     DOI: 10.1007/bf01061850

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  7 in total

1.  Concept of a volume of distribution and possible errors in evaluation of this parameter.

Authors:  S Riegelman; J Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

2.  Pharmacokinetic data. Pharmacokinetic parameters estimated from intravenous data by uniform methods and some of their uses.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1977-04

3.  Some considerations on the estimation of steady state apparent volume of distribution and the relationships between volume terms.

Authors:  P S Collier
Journal:  J Pharmacokinet Biopharm       Date:  1983-02

4.  The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time.

Authors:  S Riegelman; P Collier
Journal:  J Pharmacokinet Biopharm       Date:  1980-10

5.  A method for estimating within-individual variability in clearance and in volume of distribution from standard bioavailability studies.

Authors:  R A Upton; J F Thiercelin; J K Moore; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1982-04

6.  Intraindividual variability in theophylline pharmacokinetics: statistical verification in 39 of 60 healthy young adults.

Authors:  R A Upton; J F Thiercelin; T W Guentert; S M Wallace; J R Powell; L Sansom; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1982-04

7.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

  7 in total
  4 in total

1.  Pharmacokinetic analysis of mizolastine in healthy young volunteers after single oral and intravenous doses: noncompartmental approach and compartmental modeling.

Authors:  F Mesnil; C Dubruc; F Mentre; S Huet; A Mallet; J P Thenot
Journal:  J Pharmacokinet Biopharm       Date:  1997-04

2.  Bioavailability estimation by semisimultaneous drug administration: a Monte Carlo simulation study.

Authors:  M O Karlsson; U Bredberg
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

3.  Bioavailability of flumequine after semisimultaneous administration to veal calves.

Authors:  B A Meijer; K G Ceyssens; W T de Jong; B I de Grève
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

4.  Remoxipride--a new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers.

Authors:  M Grind; M I Nilsson; L Nilsson; G Oxenstierna; G Sedvall; A Wahlén
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.